Journal
CANCER
Volume 101, Issue 5, Pages 934-939Publisher
JOHN WILEY & SONS INC
DOI: 10.1002/cncr.20466
Keywords
neuroendocrine tumors; carcinoid; pancreatic islet cell; gemcitabine
Categories
Ask authors/readers for more resources
BACKGROUND. Treatment with traditional cytotoxic chemotherapy regimens containing streptozocin or dacarbazine has resulted in only marginal benefit for patients with metastatic neuroendocrine tumors. The use of these regimens has been further limited by their potential toxicity. Gemcitabine is generally well tolerated and possesses demonstrated activity against a wide range of malignancies. The authors assessed the efficacy of gemcitabine in the treatment of patients with metastatic neuroendocrine tumors. METHODS. Eighteen patients with metastatic neuroendocrine tumors were treated with gemcitabine administered on a standard weekly schedule. Patients were followed for evidence of toxicity, response, and survival. RESULTS. Gemcitabine was well tolerated. However, no radiologic or biochemical responses were observed. Although the majority of patients (65%) experienced disease stabilization as their best response to therapy, the overall median survival duration was only 11.5 months. CONCLUSIONS. The minimal activity of gemcitabine highlighted the need for novel treatment approaches. (C) 2004 American Cancer Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available